| Severe Combined Immunodeficiency
Cuvitru vs Bivigam
Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.Deep comparison between: Cuvitru vs Bivigam with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBivigam has a higher rate of injection site reactions vs Cuvitru based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bivigam but not Cuvitru, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cuvitru
Bivigam
At A Glance
SC injection
Daily to every 2 weeks
Immune globulin replacement (IgG)
IV infusion
Every 3-4 weeks
Intravenous immune globulin (IVIG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC infusion administered daily to every 2 weeks; patients switching from IGIV begin 1 week after last IGIV dose with initial weekly dose (g) = previous IGIV dose (g) x 1.30 divided by weeks between IGIV doses; patients switching from IGSC use the same weekly dose; monitor serum IgG trough levels to guide adjustments.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; initial infusion rate 0.5 mg/kg/min, increase every 20 minutes if tolerated up to 6 mg/kg/min; adjust dose to maintain trough IgG >= 600 mg/dL.
Contraindications
- Previous anaphylactic or severe systemic hypersensitivity reaction to subcutaneous administration of human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=5%) Local adverse reactions, headache, nausea, fatigue, diarrhea, vomiting
Postmarketing Aseptic meningitis, anaphylactic reaction, tachycardia, tremor, paresthesia, dyspnea, laryngospasm, injection site reaction (induration, warmth), chest discomfort
Most common (>=5%) Headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increased, diarrhea, dizziness, lethargy
Serious Vomiting, dehydration
Postmarketing Apnea, ARDS, TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, hemolysis, positive direct antiglobulin test, pyrexia, rigors, back pain, hepatic dysfunction, abdominal pain
Pharmacology
CUVITRU is a human IgG replacement product that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, restoring abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
BIVIGAM is an intravenous IgG replacement therapy that provides a broad spectrum of neutralizing antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins, enhancing phagocytosis and elimination of pathogens from the circulation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cuvitru
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Bivigam
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Cuvitru
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Bivigam
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cuvitru
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Bivigam
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CuvitruView full Cuvitru profile
BivigamView full Bivigam profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.